Introduction
============

Cervical cancer originates from the epithelium of cervix uteri. It is one of the most common malignant tumors in women and the fourth leading cause of cancer-associated mortality worldwide ([@b1-ol-0-0-8018]). Persistent infection of high-risk human papillomaviruses (HPVs) is associated with the progression of cervical cancer ([@b2-ol-0-0-8018]). There have been a number of efficient measures for the diagnosis and prevention of cervical cancer, including screening programs and prophylactic HPV vaccine injections for patients with cervical cancer ([@b3-ol-0-0-8018]). Surgery, chemotherapy and radiotherapy are the primary therapies for cervical cancer; however, for patients with advanced cervical cancer, these methods are ineffective due to distant metastases. Consequently, the metastasis and recurrence of cervical cancer remain the principal causes of mortality. Therefore, there is a pressing requirement to elucidate the underlying molecular mechanisms, and to explore potential biomarkers and drug targets to develop novel options for the early diagnosis and treatment of cervical cancer.

S100A6 is a member of the S100 calcium-binding protein family and its gene is located at human chromosome 1q21, where chromosomal abnormalities occur frequently ([@b4-ol-0-0-8018]). Chromosome 1q21 polyploidy was considered a high-risk characteristic for patients with multiple myeloma receiving bortezomib therapy ([@b5-ol-0-0-8018]). Chromosome 1q21 abnormalities were also associated with intellectual disability, mild dysmorphic features and congenital heart disease ([@b6-ol-0-0-8018]). Previous studies have demonstrated that S100A6 is associated with tumorigenesis and tumor progression. S100A6 promotes the proliferation and migration of human colorectal cancer cells, hepatocellular carcinoma cells, osteosarcoma cells and epithelial-mesenchymal transition (EMT) of pancreatic cancer cells ([@b7-ol-0-0-8018]--[@b10-ol-0-0-8018]). Furthermore, S100A6 is associated with the poor prognosis of patients with gastric cancer ([@b11-ol-0-0-8018]). S100A6 has also been demonstrated to be involved in a number of signaling pathways such as phosphoinositide 3-kinase (PI3K)/protein kinase (Akt) ([@b8-ol-0-0-8018]), Wnt/β-catenin ([@b10-ol-0-0-8018],[@b12-ol-0-0-8018]), p38/mitogen-activated protein kinase ([@b13-ol-0-0-8018]) and nuclear factor-κB signaling ([@b14-ol-0-0-8018]). However, to the best of our knowledge, there have not been any studies pertaining to the effect and underling molecular mechanism of S100A6 on cervical cancer at a cellular level.

The PI3K/Akt pathway is a key driver in carcinogenesis ([@b15-ol-0-0-8018]). Akt is a key signaling molecule that phosphorylates numerous downstream targets, connecting it to multiple interrelated signaling pathways. Thus, it is responsible for modulating several processes including cell survival, cell cycle progression, protein synthesis, angiogenesis and cellular migration ([@b16-ol-0-0-8018]--[@b18-ol-0-0-8018]). Akt is known to be overexpressed in many types of human cancer, and is associated with poor outcome in some cancer types ([@b19-ol-0-0-8018]). Therefore, it is hypothesized that the PI3K/Akt pathway is involved in progression of cervical cancer.

EMT is key regulator of metastasis as it facilitates tumor cell invasion and dissemination to distant organs. Standardized analysis of EMT markers in tumor biopsies may serve as a promising strategy for future clinical application ([@b20-ol-0-0-8018]). E-cadherin, N-cadherin, vimentin are EMT markers and Snail, Twist are EMT transcription factors and therefore the detection of these markers will reflect the status of EMT ([@b20-ol-0-0-8018]).

The aim of the present study was to investigate the effect of S100A6 on the proliferation and migration of cervical cancer cells and its underlying mechanisms. The present study hypothesizes that S100A6 exhibits the ability to promote the proliferation, migration and EMT of cervical cancer cells through activating PI3K/Akt signaling.

Materials and methods
=====================

### Cell culture

The human cervical cancer cell lines HeLa, SiHa and CaSki were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). Cells were maintained in Dulbecco\'s modified Eagle\'s medium (DMEM; HyClone; GE Healthcare Life Sciences, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and incubated at 37°C with 5% CO~2~.

### Recombinant adenoviruses (Ad), recombinant proteins and reagents

AdS100A6 and AdsiS100A6 \[carrying human S100A6 gene or S100A6-short interfering (si)RNA gene, respectively\] and their controls \[Ad-green fluorescent protein (GFP) or Ad-red fluorescent protein (RFP)\] were gifts from Dr He (Medical Center, The University of Chicago, Chicago, IL, USA). Untreated cells were used as blank controls. Recombinant glutathione transferase (GST) and GST-S100A6 proteins were prepared according to the protocol of Miao *et al* ([@b21-ol-0-0-8018]). The following antibodies were used: Anti-human S100A6 (cat. no. sc-50409), anti-β-catenin (cat. no. sc-59737), anti-phosphorylated (p)-Akt (cat. no. sc-33437) and anti-total (t-)Akt (cat. no. sc-8312) (all from Santa Cruz Biotechnology, Inc., Dallas, TX, USA), anti-epithelial (E)-cadherin (cat. no. 14472), anti-neuronal (N)-cadherin (cat. no. 13116), anti-p-glycogen synthase kinase 3β (GSK3β) (cat. no. 9323), anti-t-GSK3β (cat. no. 9315) (all from Cell Signaling Technology, Inc., Danvers, MA, USA), anti-E-cadherin for HeLa cells (cat. no. YM3353; ImmunoWay Biotechnology Company, Plano, TX, USA), anti-β-actin (cat. no. TA-09; OriGene Technologies, Inc., Beijing, China) and goat anti-rabbit antibody (cat. no. ZB-2301) or goat anti-mouse antibody (cat. no. ZB-2305) (OriGene Technologies, Inc.). MTT (Beyotime Biotechnology, Shanghai, China). Hoechst 33258 (Beyotime Institute of Biotechnology, Haimen, China) and the PI3K inhibitor LY294002 (MedChemExpress, Monmouth Junction, NJ, USA) were dissolved in dimethyl sulfoxide (DMSO) to a concentration of 10 mM.

### RNA extraction, reverse transcription (RT), qPCR and semi-qPCR

Total RNA was extracted from the cervical cancer cell lines using RNAiso Plus (Takara Biotechnology Co., Ltd., Dalian, China). RT reactions were performed according to the manufacturer\'s instructions (Takara Biotechnology Co., Ltd.). Semi-qPCR was performed according to the protocol of Duan *et al* ([@b22-ol-0-0-8018]). Taq DNA polymerase was purchased from Takara Biotechnology Co., Ltd., and the cDNA products were further diluted 5-fold and used in subsequent experiments. Cycling conditions were as follows: 94°C for 5 min, 94°C for 30 sec, 68°C for 30 sec and 72°C for 12 cycles with a decrease in 1°C/cycle; then, 94°C for 30 sec, 55°C for 30 sec, and 72°C for 30 sec for 18--27 cycles depending on the abundance of the target genes. The PCR products were separated using 2% agarose gel and stained with ethidium bromide. The results were recorded using the Gel imaging system (GelDoc 1000; Bio-Rad Laboratories, Inc., Hercules, CA, USA) and analyzed using Quantity One (version 4.5.0; Bio-Rad Laboratories, Inc.).

qPCR was performed on the CFX96 real-time PCR detection system from Bio-Rad Laboratories, Inc. using SYBR Premix Ex Taq™ II (Takara Biotechnology Co., Ltd.). Data were collected and analyzed using the comparative 2^−ΔΔCt^ method ([@b23-ol-0-0-8018]). GAPDH was used as control. All primers used in the present study are presented in [Table I](#tI-ol-0-0-8018){ref-type="table"}.

### Western blot analysis

Total protein was extracted using radioimmunoprecipitation assay lysis buffer (Beyotime Biotechnology) in the presence of protease inhibitor (Complete EasyPack; Roche Applied Science, Penzberg, Germany) and phosphatase inhibitor (PhosSTOP; Roche Applied Science) at 72 h after treatment with recombinant adenoviruses or recombinant proteins. Protein was quantified using spectrophotometry (Thermo Fisher Scientific, Inc.) at 280 nm. Protein (300 µg loaded per lane) was separated using SDS-PAGE (10% gel) and transferred onto polyvinylidene fluoride membranes (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). The membranes were blocked with 5% bovine serum albumin (Solarbio, Beijing, China) at 37°C for 2 h and incubated with primary antibodies (dilution 1:1,000) overnight at 4°C. The membranes were washed with Tris-buffered saline with Tween-20 and incubated with horseradish peroxidase (HRP) conjugated secondary antibody (dilution 1:5,000) for 1 h at 37°C. Finally, the membranes were exposed using Immobilon western chemiluminescent HRP substrate (EMD Millipore, Billerica, MA, USA). Results were recorded using the Bio-Rad electrophoresis documentation system (Gel Doc 1000; Bio-Rad Laboratories, Inc.) and Quantity One software (version 4.5.0; Bio-Rad Laboratories, Inc.).

### Cell viability assay

Cell viability was determined using the MTT assay according to the protocol of Duan *et al* ([@b7-ol-0-0-8018]).

### Hoechst staining assay

Cells were seeded (3×10^4^ cells/well) in a 24-well plate and incubated at 37°C overnight, then treated with recombinant adenoviruses for 72 h when cells were \~30% confluent. Cells were then fixed with 4% paraformaldehyde for 15 min, washed with PBS three times, stained with 100 µl Hoechst 33258 solution (dilution 1:1,000; Beyotime Institute of Biotechnology) for 30 min and washed with PBS a further three times. Images were captured under an inverted fluorescence microscope (magnification, ×100 and ×400). When the cell was apoptotic, the nucleus was stained bright blue. The ratio of the number of apoptotic cells to the total number of cells in a randomly given field of view was calculated as the rate of apoptosis.

### Wound healing assay

Cells were seeded (3×10^5^ cells/well) into a six-well plate and treated with recombinant adenoviruses for 72 h when cells reached 95% confluency. The wound healing assay was performed according to the protocol of Duan *et al* ([@b7-ol-0-0-8018]).

### Transwell assay

The Transwell inserts were purchased from EMD Millipore. Cells were seeded (1.5×10^5^ cells/well) in a 6-well plate and treated with recombinant adenoviruses or recombinant proteins for 72 h when cells were \~30% confluent. The treated cells were collected and 4×10^4^ cells were resuspended in 400 µl serum-free DMEM and seeded in the upper chamber, another 600 µl medium with 20% FBS was added to the lower chamber. Following incubation for 24 h, chambers were fixed with 4% paraformaldehyde for 15 min and then stained with 0.05% crystal violet for 15 min at room temperature. The transmembrane cells were counted using inverted microscopy (magnification, ×100) in 10 different views for each insert and images were captured. The relative cell number per field was calculated as follows; number of cells in each group/number of cells in the blank group.

### Statistical analysis

Results are presented as the mean ± standard deviation. A one-way analysis of variance, followed by the Student-Newman-Keuls test was used to analyze the statistical significance of differences among groups, and all analyses were performed using GraphPad Prism software (version 5; GraphPad Software, Inc., La Jolla, CA, USA). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### S100A6 promotes the proliferation of cervical cancer cells

To examine the effect of S100A6 on cervical cancer cells, the expression of S100A6 was detected in the three cervical cancer cell lines HeLa, SiHa and CaSki. The qPCR results demonstrated that the S100A6 mRNA level was comparatively lower in HeLa cells. As presented in [Fig. 1A](#f1-ol-0-0-8018){ref-type="fig"}, the mRNA levels of S100A6 in SiHa and CaSki cells were increased 6.92- and 7.54-fold compared with those of HeLa cells respectively (P\<0.005). The S100A6 level of HeLa and CaSki cells was upregulated by AdS100A6, and the S100A6 level of SiHa and CaSki cells was downregulated by AdsiS100A6 as was demonstrated by western blot analysis ([Fig. 1B](#f1-ol-0-0-8018){ref-type="fig"}).

To investigate whether S100A6 is involved in the proliferation of cervical cancer cells, the MTT assay was performed. Cell proliferation ability was significantly increased following treatment with AdS100A6 for 72 h in HeLa and CaSki cells (P\<0.01 and P\<0.005 respectively; [Fig. 1C](#f1-ol-0-0-8018){ref-type="fig"}), whereas it was markedly decreased following treatment with AdsiS100A6 for 72 h in SiHa and CaSki cells (P\<0.05; [Fig. 1D](#f1-ol-0-0-8018){ref-type="fig"}). The effect of S100A6 on cellular apoptosis was investigated using Hoechst staining and no marked changes were identified between the examined groups in number of apoptosis cells ([Fig. 1E and F](#f1-ol-0-0-8018){ref-type="fig"}). These results demonstrated that S100A6 is able to promote the proliferation of cervical cancer cells and had no significant effect on the apoptosis of cells.

### S100A6 promotes the migration and EMT of cervical cancer cells

Wound healing and Transwell assays were performed to investigate the effect of S100A6 on cell migration. In the present study, AdGFP was a control of AdS100A6 and AdRFP was a control of AdsiS100A6. Furthermore, CaSki cells were treated with AdS100A6 and AdsiS100A6 in order to upregulate or downregulate the level of S100A6, respectively. The present study used AdS100A6 to upregulate the level of S100A6 in HeLa cells, and AdsiS100A6 to down-regulate the level of S100A6 in SiHa cells. Following the upregulation of S100A6 by AdS100A6 for 72 h, the wound healing rates were increased 2.1- (P\<0.05) and 3.6-fold (P\<0.01) compared with those of the AdGFP groups in HeLa and CaSki cells ([Fig. 2A](#f2-ol-0-0-8018){ref-type="fig"}). Conversely, following the downregulation of S100A6 by AdsiS100A6 for 72 h, the wound-healing rates were decreased by 41% (P\<0.05) and 44% (P\<0.05) of that in their respective AdRFP groups ([Fig. 2B](#f2-ol-0-0-8018){ref-type="fig"}). The migratory ability of cells was further confirmed by a Transwell assay. Following treatment with AdS100A6, the number of transmembrane cells were increased \~5- (P\<0.005) and 2-fold (P\<0.01) compared with that in the AdGFP groups of HeLa and CaSki cells ([Fig. 2C](#f2-ol-0-0-8018){ref-type="fig"}). However, following treatment with AdsiS100A6, the number of transmembrane cells were decreased by 66% (P\<0.005) and 65% (P\<0.01) compared with those of their respective AdRFP groups ([Fig. 2D](#f2-ol-0-0-8018){ref-type="fig"}). These results indicated that S100A6 promoted cell migration.

Additionally, upregulation of S100A6 in HeLa cells increased the mRNA levels of N-cadherin, vimentin, Snail and Twist, and decreased the protein level of E-cadherin, whereas the downregulation of S100A6 in SiHa cells induced the opposite effect ([Fig. 2E](#f2-ol-0-0-8018){ref-type="fig"}). Collectively, these results indicated that S100A6 was able to induce EMT in cervical cancer cells.

### S100A6 activates the PI3K/Akt signaling pathway and promotes the viability and migration of cervical cancer cells

To explore the predominant downstream signaling pathway of S100A6, the alteration of several pathway proteins were evaluated using western blotting. The phosphorylation level of Akt and its downstream target genes p-GSK3β and β-catenin were demonstrated to be increased in the AdS100A6 group of HeLa cells, and was consistent with activation of the PI3K/Akt pathway ([Fig. 3A](#f3-ol-0-0-8018){ref-type="fig"}). To further validate the involvement of PI3K/Akt activation in S100A6-enhanced proliferation and migration of cervical cancer cells, a pharmacological approach was adopted. HeLa cells were treated with the PI3K inhibitor LY294002 (10 µM) alone, or combined with GST-S100A6 (10 µg/ml). The level of p-Akt, p-GSK3β and β-catenin were decreased when the PI3K/Akt pathway was blocked using the PI3K inhibitor LY294002 ([Fig. 3B](#f3-ol-0-0-8018){ref-type="fig"}). Furthermore, LY294002 significantly impaired the S100A6-enhanced proliferation and migration of HeLa cells (P\<0.005; [Fig. 3C and D](#f3-ol-0-0-8018){ref-type="fig"}). Taken together, these results suggest that S100A6 promotes the proliferation and migration of cervical cancer cells through the PI3K/Akt signaling pathway.

Discussion
==========

Cervical cancer is a common tumor of the female reproductive system with a high metastatic potential and mortality. Although infection with HPV is considered to be a principal cause of cervical cancer, there are a variety of risk factors associated with the morbidity of cervical cancer, including reproductive and nutritional factors, and other types of pathogen infection including chlamydia trachomatis, herpes simplex virus type II and trichomonad. The presence of these additional risk factors provides additional difficulties in the identification of novel potential biomarkers for the detection and therapy of cervical cancer.

There have been a number of studies investigating the role of S100A6 in tumorigenesis and tumor development. The results provide evidence that S100A6 promotes proliferation and migration in colorectal cancer cells ([@b7-ol-0-0-8018]), pancreatic cancer cells ([@b24-ol-0-0-8018]) and other malignant tumor cells ([@b9-ol-0-0-8018]). A previous study indicated that the level of S100A6 differs in different cervical lesion tissues, and its expression is positively associated with the degree of cervical lesion, invasion and metastasis ([@b25-ol-0-0-8018]). S100A6 was markedly expressed in cervical cancer tissues, and is predominantly expressed in fibroblasts and epithelial cells of the breast, heart, intestine, kidney, liver, ovary, placenta, stomach, thymus and uterus ([@b26-ol-0-0-8018]). Furthermore, increased expression of S100A6 has been identified in tumors ([@b27-ol-0-0-8018]). To the best of our knowledge, no previous studies have been performed that investigate the level of S100A6 in normal epithelial cell lines of cervix uteri. This was a limitation of the present study and it is therefore a recommendation for future studies in this field. The results of the present study demonstrated that S100A6 serves an important role in promoting the proliferation and migration of cervical cancer cells through the PI3K/Akt signaling pathway.

HPV16 and HPV18 are the most common types of cervical cancer and account for \~67% of all cervical carcinomas worldwide ([@b28-ol-0-0-8018]). HeLa cells are HPV18^+^ whereas SiHa cells are HPV16^+^, and HPV16^+^ and HPV18^+^ cervical cancer exhibit different biological behavior *in vivo* ([@b29-ol-0-0-8018]). This is due to the E6 and E7 gene products of HPV contributing to the pathogenesis of cancer. HPV integrates with the DNA within the host cell nucleus and thereby dysregulates the expression of the oncoproteins E6 and E7. Degradation of p53 is induced by E6, which results in a loss of p53 activity. Its degradation is accomplished through the formation of a complex with p53, E6 and E6-associated protein ([@b30-ol-0-0-8018]). In a physiological state, p53 functions to arrest cells in the G~1~ phase of the cell cycle and induces apoptosis to allow the repair of host DNA ([@b30-ol-0-0-8018]). Furthermore, E7 binds to the cyclin-dependent kinase inhibitor, which results in a loss of control over the cell cycle ([@b30-ol-0-0-8018]). HeLa and SiHa are two different cell types, with different types of HPV; this is a potential explanation for why, in the present study, the S100A6 levels varied between the two cell lines.

In the present study, cervical cancer cells were treated with AdS100A6 and AdsiS100A6 to upregulate and downregulate the level of S100A6. The results of the present study suggest that S100A6 promotes the proliferation of cervical cancer cells, and these results were consistent with those of previous studies in colorectal cancer ([@b7-ol-0-0-8018]), hepatocellular carcinoma ([@b8-ol-0-0-8018],[@b31-ol-0-0-8018]) and osteosarcoma ([@b9-ol-0-0-8018]). A Hoechst staining assay was performed to provide a visual result; however, there are human errors associated with the manual analysis and counting of cells. Consequently, the absence of flow cytometric data to detect apoptosis is a limitation of the present study. Furthermore, S100A6 was demonstrated to significantly promote the migration of cervical cancer cells, which is in accordance with a previous study on pancreatic duct adenocarcinoma ([@b10-ol-0-0-8018]). These results imply that S100A6 facilitates the metastasis of cervical cancer cells, as cell invasion and migration are the basic steps for tumor metastasis. Therefore, S100A6 may contribute to cervical cancer metastasis and may be a potential target for the treatment of cervical cancer, in order to increase the survival period of patients. However, the absence of data regarding the regulatory effect of S100A6 on cell invasion is a limitation of the present study.

A number of studies have reported that EMT has become a principal factor for tumor malignancy, as EMT contributes to the motility and invasiveness of tumor cells, and therefore contributes to distant metastasis ([@b32-ol-0-0-8018]--[@b34-ol-0-0-8018]). Cancer-associated EMT is a complicated and comprehensive reprogramming process that is involved in the metabolism, epigenetics and differentiation of cells ([@b35-ol-0-0-8018]). Previous studies have demonstrated that claudin-1, oncostatin-M receptor and lysine-specific demethylase 1 are associated with EMT and a poor outcome in cervical cancer ([@b36-ol-0-0-8018]--[@b38-ol-0-0-8018]). The results of the present study confirmed that S100A6 induced EMT in cervical cancer cells. Therefore, EMT serves an important role in the progression of cervical cancer. HeLa cells expressed lower levels of S100A6 and SiHa cells expressed higher levels of S100A6. Consequently, an increased level of S100A6 was attributed to the higher mesenchymal properties of SiHa cells. The level of E-cadherin was increased in HeLa cells compared with that of SiHa cells, whereas the level of N-cadherin was the opposite. These are consistent with the hypothesis that a function of S100A6 is to induce EMT in cervical cancer cells. In the present study, the expression of these molecules were determined by western blotting or semi-qPCR. A limitation of the present study is that the expression of these molecules was determined only at the mRNA or protein level.

A number of studies have demonstrated the involvement of S100A6 in a number of signaling pathways in many types of cancer cell ([@b7-ol-0-0-8018]--[@b14-ol-0-0-8018]). In cervical cancer cells, a number of pathways are implicated in cellular proliferation, apoptosis, migration and invasion, including Wnt/β-catenin, mTOR and ERK signaling ([@b39-ol-0-0-8018]--[@b42-ol-0-0-8018]). In the present study, the PI3K/Akt signaling pathway was selected to determine the effect of S100A6 on cell proliferation and migration of cervical cancer cells. This is due to the PI3K/Akt signaling pathway serving an important role in tumorigenesis and the regulation of critical cellular functions, including survival, proliferation and metabolism ([@b43-ol-0-0-8018]). An increasing amount of evidence has demonstrated that the PI3K/Akt pathway is involved in the proliferation, apoptosis and autophagy of cervical cancer cells ([@b44-ol-0-0-8018]--[@b46-ol-0-0-8018]). It has been reported that Akt and matrix metalloproteinase 3 are key regulators of EMT in cervical cancer ([@b47-ol-0-0-8018]). It has also been suggested that the PI3K/Akt signaling pathway promotes metastasis and EMT in nasopharyngeal carcinoma ([@b48-ol-0-0-8018]). In our previous study, it was demonstrated that S100A6 may promote the proliferation and migration of osteosarcoma cells via the PI3K/Akt signaling pathway ([@b49-ol-0-0-8018]). Therefore, an aim of the present study was to determine whether the PI3K/Akt signaling pathway was also involved in S100A6-enhanced proliferation and migration of cervical cancer cells. GST-S100A6 and LY294002 were chosen to further validate the involvement of PI3K/Akt activation in S100A6-enhanced proliferation and migration of cervical cancer cells. The results demonstrated that S100A6 activated the PI3K/Akt signaling pathway and inhibition of the PI3K/Akt pathway markedly impaired S100A6-enhanced proliferation and migration of HeLa cells. Similar experiments were performed using AdS100A6; however, when cells were co-treated with AdS100A6 and LY294002, a large cohort of cells immediately underwent apoptosis due to the toxicity of polybrene and DMSO. Consequently, GST-S100A6 was used as it has a similar effect to AdS100A6 and is less toxic ([@b50-ol-0-0-8018]). Receptor for advanced glycation end-products (RAGE), Toll-like receptor 4 and epidermal growth factor receptors are receptors of the S100 protein, and S100A6 activates RAGE through distinct signal transduction pathways ([@b51-ol-0-0-8018]--[@b53-ol-0-0-8018]). Previous research of the present study cohort has demonstrated that S100A6 is an exocrine protein that can be secreted to the extracellular space, and the secreted S100A6 protein in the cell culture medium upregulated the mRNA level of endogenous S100A6 through Wnt/β-catenin signaling. This subsequently affected the biological characteristics of tumor cells ([@b50-ol-0-0-8018]) and GST-S100A6 was demonstrated to act similarly to AdS100A6 ([@b50-ol-0-0-8018]). The secreted S100A6 protein was able to promote the proliferation and migration of colorectal cancer cells ([@b50-ol-0-0-8018]). Further research is required to explore the effects of LY294002 on EMT. Collectively, these results suggest that S100A6 promotes the proliferation and migration of cervical cancer cells through the PI3K/Akt signaling pathway.

In conclusion, the results of the present study demonstrate that S100A6 serves a pivotal role in the malignancy of cervical cancer cells, including promoting the proliferation, migration and EMT of cervical cancer cells by activating the PI3K/Akt signaling pathway. The present study provides evidence to improve the understanding of the pathophysiological process of cervical cancer as S100A6 may be a promising molecular target for patients with cervical cancer. However, the absence of *in vivo* data and data regarding the expression and clinical significance of S100A6 in cervical cancer tissues are limitations of the present study. Therefore, further *in vivo* studies and data regarding the expression and clinical significance of S100A6 in cervical cancer tissues based on *in vivo* studies and databases including Oncomine are required to verify these issues and confirm the role of S100A6 as a novel biomarker for the detection and therapy of cervical cancer.
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![S100A6 promotes the proliferation of cervical cancer cells (A) qPCR was used to analyze the mRNA levels of S100A6 in the cervical cancer cell lines HeLa, SiHa and CaSki. (B) AdS100A6 infected HeLa and CaSki cells, AdsiS100A6 infected CaSki and SiHa cells. The infection efficiency was determined by western blotting. Cell proliferation was detected using an MTT assay in (C) HeLa and CaSki cells following treatment with AdS100A6 and in (D) SiHa and CaSki cells following treatment with AdsiS100A6. Cell apoptosis was determined by Hoechst staining assay in (E) HeLa and CaSki cells after treatment with AdS100A6 and in (F) SiHa and CaSki cells following treatment with AdsiS100A6. As no significant changes were identified between all groups in number of apoptosis cells, no quantitative data was provided. \*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.005 compared with the AdGFP or AdRFP groups. All the experiments were repeated three times. Results were presented as the mean ± standard deviation. A one-way analysis of variance, followed by the Student-Newman-Keuls test was used to analyze the statistical significance of differences among groups. OD, optical density; nm, nanometer; AdGFP, adenovirus carrying green fluorescent protein; AdS100A6, adenovirus carrying S100A6; AdRFP, adenovirus carrying red fluorescent protein; AdsiS100A6, adenovirus carrying S100A6-short interfering RNA gene; E-cadherin, epithelial cadherin; N-cadherin, neuronal cadherin.](ol-15-04-5685-g00){#f1-ol-0-0-8018}

![S100A6 promotes the migration and EMT of cervical cancer cells. Cell migration ability was detected using a wound healing assay. The wound width of sites was measured and the wound healing rate of (A) HeLa and CaSki cells with AdGFP, and (B) SiHa and CaSki with AdRFP was calculated. The wound healing rate was calculated as follows; (width at 0 h-width at 72 h)/width at 0 h ×100%. Cell migration ability of (C) HeLa and CaSki cells with AdGFP, and (D) SiHa and CaSki cells with AdRFP were detected using a Transwell assay, where the number of transmembrane cells were counted and the relative cell number per field was calculated. The relative cell number per field = number of cells in per field of treatment group/number of cells in per field of blank group. (E) The protein levels of E-cadherin and N-cadherin were determined using western blotting and the mRNA levels of vimentin, Snail and Twist were determined using semi-quantitative PCR in HeLa and SiHa cells. \*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.005 compared with the AdGFP or AdRFP groups. All experiments were repeated for three times. Results were presented as the mean ± standard deviation. A one-way analysis of variance, followed by the Student-Newman-Keuls test was used to analyze the statistical significance of differences among groups. EMT, epithelial-mesenchymal transition; AdGFP, adenovirus carrying green fluorescent protein; AdS100A6, adenovirus carrying S100A6; AdRFP, adenovirus carrying red fluorescent protein; AdsiS100A6, adenovirus carrying S100A6-short interfering RNA gene; E-cadherin, epithelial cadherin; N-cadherin, neuronal cadherin.](ol-15-04-5685-g01){#f2-ol-0-0-8018}

![S100A6 activates the PI3K/Akt signaling pathway and promotes the viability and migration of cervical cancer cells. (A) HeLa cells were treated with AdS100A6 or AdGFP for 72 h. Total Akt, total GSK3β, β-catenin, p-Akt and p-GSK3β were detected using western blotting. (B) HeLa cells were treated with GST-S100A6 and LY294002 for 72 h, and total Akt, total GSK3β, β-catenin, p-Akt and p-GSK3β were detected using western blotting. (C) The effect of LY294002 on S100A6-enhanced proliferation of HeLa cells was determined using an MTT assay. HeLa cells were treated with GST-S100A6 (10 µg/ml) and LY294002 (10 µM) for 72 h. (D) The effect of LY294002 on S100A6-enhanced migration of HeLa cells was determined by a Transwell assay (magnification, ×100). HeLa cells were treated with GST-S100A6 (10 µg/ml), LY294002 (10 µM) or DMSO for 72 h. The number of transmembrane cells were counted and calculated. All experiments were repeated three times. Results were presented as the mean ± standard deviation. A one-way analysis of variance, followed by the Student-Newman-Keuls test was used to analyze the statistical significance of differences among groups. \*P\<0.05, \*\*\*P\<0.005, DMSO + GST-S100A6 group compared with LY2940002 + GST-S100A6 group. p, phosphorylated; t, total; AdGFP, adenovirus carrying green fluorescent protein; AdS100A6, adenovirus carrying S100A6; OD, optical density; GST, glutathione transferase; DMSO, dimethyl sulfoxide.](ol-15-04-5685-g02){#f3-ol-0-0-8018}

###### 

Primer sequences.

  Gene       Primer sequence                        Product size, bp
  ---------- -------------------------------------- ------------------
  S100A6     Forward, 5′-ATGGCATGCCCCTGGATCAGG-3′   272
             Reverse, 5′-TCAGCCCTTGAGGGCTTCAT-3′    
  Vimentin   Forward, 5′-TTGAACGCAAAGTGGAAT-3′      136
             Reverse, 5′-AGGTCAGGCTTGGAAACA-3′      
  Snail      Forward, 5′-ACCCCACATCCTTCTCACTG-3′    217
             Reverse, 5′-TACAAAAACCCACGCAGACA-3′    
  Twist      Forward, 5′-TCTTACGAGGAGCTGCAGAC-3′    406
             Reverse, 5′-TATCCAGCTCCAGAGTCTCT-3′    
  GAPDH      Forward, 5′-CAGCGACACCCACTCCTC-3′      120
             Reverse, 5′-TGAGGTCCACCACCCTGT-3′      
